ImmunoGen narrows loss; Boehringer gets Trajenta extension; Unichem targets Forest's Namenda;

@FiercePharma: Boehringer Ingelheim settles marketing case for just $95M. Story | Follow @FiercePharma

> ImmunoGen ($IMGN) on Friday said that its fiscal first-quarter loss widened 29%, as it spent more money developing its experimental drugs. Story

> Boehringer Ingelheim and Eli Lilly ($LLY) have gotten approval from the EU for Trajenta to be used in conjunction with insulin in adults with Type 2 Diabetes. Release 

> While there are no trials showing improved survival rate, Teva Pharmaceutical Industries ($TEVA) said the FDA approved its Synribo for injection to treat adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors based on response rate. Release

> Indian drugmaker Unichem Laboratories claims it has received tentative approval from the FDA to make a generic version of Forest Laboratories' ($FRX) Namenda tablets for treating Alzheimer's disease and that final approval will come after the patent expires April 11, 2015. Story 

> A federal judge has granted a permanent injunction against Truman J. Berst and Alternative Health & Herbs Remedies of Albany, OR, for selling herbs and supplements that include claims that they will treat medical conditions. Release

Medical Device News

 @FierceMedDev: Varian Medical Systems booked a banner Q4. Response: investors drove the stock price up more than 16%. Release | Follow @FierceMedDev

 @MarkHFierce: Philips and Elekta are beefing up a joint program focused on blending a linear accelerator with MRI. Release | Follow @MarkHFierce

 @DamianFierce: Bayer has called off the sale of its glucose meter business, according to a German newspaper. Report | Follow @DamianFierce

> Philips, Elekta consortium building MRI/radiation treatment system. News

> St. Jude dealt a blow with heart-plug study. Report

Biotech News

 @FierceBiotech: High blood pressure medicine boosts memories of Alzheimer's-stricken mice. Article | Follow @FierceBiotech

 @RyanMFierce: Novo is confident in heart safety of degludec, Reuters reports. Gotta make the case to Nov. 8 FDA panel, though. More | Follow @RyanMFierce

> Puma Biotech raises $138M in public offering to advance cancer drug from Pfizer. News

> ViaCyte, Bluebird score $19.4M in CA stem cell funds for game-changing therapies. News

> FDA homes in on cardio risks of Novo Nordisk's key diabetes therapy. More

And Finally... Johnson & Johnson ($JNJ) picked IPG's UM and GroupM's MEC to handle its media buying and planning for the EMEA markets, a contract estimated to be worth $322 million. Story

Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.